FDA Approves Monthly Dosing for Leqembi, Boosting Alzheimer’s Treatment Accessibility
28 Jan 2025
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi, an Alzheimer's drug developed by Japan's Eisai in partnership with Biogen. This approval marks a significant milestone in Alzheimer's treatment, providing a more convenient dosing schedule for patients. Leqembi, which received standard approval from the FDA...
Read More